Conformationally-preorganized, MiniPEG-containing gamma-peptide nucleic acids

US11279736B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-11279736-B2
Application numberUS-202017003131-A
CountryUS
Kind codeB2
Filing dateAug 26, 2020
Priority dateApr 8, 2011
Publication dateMar 22, 2022
Grant dateMar 22, 2022

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention relates to γ-PNA monomers according to Formula I where substituent groups R1, R2, R3, R4, R5, R6, B and P are defined as set forth in the specification. The invention also provides methodology for synthesizing compounds according to Formula I and methodology for synthesizing PNA oligomers that incorporate one or more Formula I monomers.

First claim

Opening claim text (preview).

What is claimed is: 1. A compound according to Formula I wherein B is a nucleic acid base; R 1 , R 2 and R 5 each independently is selected from the group consisting of H, linear or branched (C 1 -C 8 )alkyl, and —CH 2 —(OCH 2 —CH 2 ) q OP 1 , provided that at least one of R 1 and R 2 independently is —CH 2 —(OCH 2 —CH 2 ) q OP 1 ; R 3 and R 4 each independently is H; R 6 is selected from the group consisting of H, linear or branched (C 1 -C 8 )alkyl, substituted or unsubstituted (C 3 -C 8 )aryl and (C 3 -C 8 )aryl(C 1 -C 6 )alkylene; P is selected from the group consisting of H, 9-fluorenylmethyloxy carbonyl, Boc, benzyloxycarbonyl, tosylate, benzyl, alloc, trityl, dimethoxytrityl and monomethoxytrityl; P 1 is selected from the group consisting of H, (C 1 -C 8 )alkyl, (C 2 -C 8 )alkenyl, (C 2 -C 8 )alkynyl, (C 3 -C 8 )aryl, (C 3 -C 8 )cycloalkyl, (C 3 -C 8 )aryl(C 1 -C 6 )alkylene and (C 3 -C 8 )cycloalkyl(C 1 -C 6 )alkylene; n is an integer between 0 and 10 inclusive, and q is an integer between 1 and 10 inclusive. 2. The compound according to claim 1 , wherein each of R 1 and R 2 is independently —CH 2 —O—(CH 2 -CH 2 —O) q P 1 . 3. The compound according to claim 2 , wherein R 1 is —CH 2 —(O—CH 2 —CH 2 ) n OP 1 and R 2 is selected from the group consisting of H and linear or branched (C 1 -C 8 )alkyl. 4. The compound according to claim 3 , wherein R 1 is —CH 2 —(O—CH 2 —CH 2 ) q OP 1 and R 2 is H. 5. The compound according to claim 4 , wherein P 1 is H or (C 1 -C 8 )alkyl. 6. The compound according to claim 1 , having stereochemical purity in the range from about 80% to about 99% at the Cγ-position. 7. The compound according to claim 6 , having stereochemical purity of at least 90% at the Cγ-position. 8. The compound according to claim 6 , having stereochemical purity of at least 99% at the Cγ-position. 9. A method for synthesizing a peptide nucleic acid (PNA) oligomer having a pre-determined sequence, comprising: (a) activating the carboxylic acid group of an allyl linker according to Formula (b) contacting a solid support with the activated allyl linker; (c) activating the carboxylic acid group of a first amino protected PNA monomer or an amino protected γPNA monomer depending on the PNA oligomer sequence and then contacting the activated carboxylic acid monomer to the product from step (b); (d) de-protecting the amino group of the product from step (c); (e) contacting the product from step (d) with a second sequence specific PNA monomer or a γ-PNA monomer; and (f) repeating steps (c), (d) and (e) to synthesize the peptide nucleic acid (PNA) oligomer comprising at least one PNA monomer; wherein the γ-PNA monomer is a compound according to Formula I wherein B is a nucleic acid base selected from adenine, guanine, cytosine, thymine or uracil; R 1 R 2 and R 5 each independently is selected from the group consisting of H, linear or branched (C 1 -C 8 )alkyl, (C 2 -C 8 )alkenyl, (C 2 -C 8 )alkynyl, (C 1 -C 8 )hydroxyalkyl, (C 3 -C 8 )aryl, (C 3 -C 8 )cycloalkyl, (C 3 -C 8 )aryl(C 1 -C 6 )alkylene, (C 3 -C 8 )cycloalkyl(C 1 -C 6 )alkylene, —CH 2 —(OCH 2 —CH 2 ) q —OP 1 , —CH 2 —(OCH 2 —CH 2 ) q —NHP1, —CH 2 —(OCH 2 —CH 2 ) q —SP 1 and —CH 2 —(SCH 2 —CH 2 ) q —SP 1 ; R 3 and R 4 each independently is H; R 6 is selected from the group consisting of H, linear or branched (C 1 -C 8 )alkyl, substituted or unsubstituted (C 3 -C 8 )aryl and (C 3 -C 8 )aryl(C 1 -C 6 )alkylene; P is selected from the group consisting of H, 9-fluorenylmethyloxy carbonyl, Boc, benzyloxycarbonyl, tosylate, benzyl, alloc, trityl, dimethoxytrityl and monomethoxytrityl; P 1 is selected from the group consisting of H, (C 1 -C 8 )alkyl, (C 2 -C 8 )alkenyl, (C 2 -C 8 )alkynyl, (C 3 -C 8 )aryl, (C 3 -C 8 )cycloalkyl, (C 3 -C 8 )aryl(C 1 -C 6 )alkylene and (C 3 -C 8 )cycloalkyl(C 1 -C 6 )alkylene; and n and q each independently is an integer between 0 and 10 inclusive. 10. The method of claim 9 , wherein steps (a) through (f) are performed using an automated solid-phase synthesizer. 11. The compound of claim 1 , wherein B is adenine. 12. The compound of claim 1 , wherein B is guanine. 13. The compound of claim 1 , wherein B is cytosine. 14. The compound of claim 1 , wherein B is thymine. 15. The compound of claim 1 , wherein B is uracil.

Assignees

Inventors

Classifications

  • One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine · CPC title

  • as doubly bound oxygen atoms or as unsubstituted hydroxy radicals · CPC title

  • C07K14/003Primary

    Peptide-nucleic acids (PNAs) · CPC title

  • attached in position 6, e.g. adenine · CPC title

  • using activating agents {(C07K1/003, C07K1/006 take precedence)} · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US11279736B2 cover?
The present invention relates to γ-PNA monomers according to Formula I where substituent groups R1, R2, R3, R4, R5, R6, B and P are defined as set forth in the specification. The invention also provides methodology for synthesizing compounds according to Formula I and methodology for synthesizing PNA oligomers that incorporate one or more Formula I monomers.
Who is the assignee on this patent?
Univ Carnegie Mellon
What technology area does this patent fall under?
Primary CPC classification C07K14/003. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Mar 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 5 related publications on this page (citations in our corpus or others sharing the same primary CPC).